CRL (CRL) CEO shifts 6,772 shares via bona fide gifts, keeps large stake

Rhea-AI Filing Summary

Charles River Laboratories' CEO Birgit Girshick reported exempt insider transfers primarily structured as gifts rather than market sales. She made bona fide gifts totaling 6,772 shares of Common Stock on June 5, 2026, including a transfer of 3,386 shares to a revocable trust she controls under Rule 16a-13.

Following these transfers, she holds 36,013 Common shares directly and 43,803 shares indirectly through the revocable trust. She also holds stock options covering 8,722 shares of Common Stock, exercisable at $208.44 per share and expiring on May 31, 2034. These transactions did not involve any sale proceeds.

Insider Trade Summary

6,772 shares gifted

Mixed 3 txns

Insider Girshick Birgit

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Gift	Common Stock	3,386	$0.00	--
Gift	Common Stock	3,386	$0.00	--
holding	Stock Options (Right to Buy)	--	--	--

Holdings After Transaction: Common Stock — 36,013 shares (Direct, null); Common Stock — 43,803 shares (Indirect, Revocable Trust); Stock Options (Right to Buy) — 8,722 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares gifted: 6,772 shares Direct common shares after gifts: 36,013 shares Indirect common shares after gifts: 43,803 shares +2 more

5 metrics

Shares gifted 6,772 shares Total bona fide gifts of Common Stock on June 5, 2026

Direct common shares after gifts 36,013 shares Direct CRL Common Stock held by CEO after reported transactions

Indirect common shares after gifts 43,803 shares Indirect CRL Common Stock held through revocable trust after transfers

Stock option exercise price $208.44/share Exercise price of options over 8,722 CRL shares

Underlying shares for options 8,722 shares Common Stock underlying CEO stock options expiring May 31, 2034

Key Terms

bona fide gift, Rule 16a-13, revocable trust, Stock Options (Right to Buy)

4 terms

bona fide gift financial

"transaction_code_description": "Bona fide gift""

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

Rule 16a-13 regulatory

"Reflects the exempt transfer pursuant to Rule 16a-13 of 3,386 shares"

revocable trust financial

"to a revocable trust controlled by the reporting person"

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

Stock Options (Right to Buy) financial

"security_title": "Stock Options (Right to Buy)""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Girshick Birgit

(Last) (First) (Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON MASSACHUSETTS 01887

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		G		3,386(1)	D	$0	36,013	D
Common Stock	06/05/2026		G		3,386(1)	A	$0	43,803	I	Revocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$208.44							05/31/2025	05/31/2034	Common Stock	8,722		8,722	D

Explanation of Responses:

1. Reflects the exempt transfer pursuant to Rule 16a-13 of 3,386 shares held by the reporting person to a revocable trust controlled by the reporting person.

	/s/ Birgit Girshick	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did CRL CEO Birgit Girshick report on June 5, 2026?

Birgit Girshick reported bona fide gifts totaling 6,772 Charles River Laboratories (CRL) common shares on June 5, 2026. The gifts included 3,386 shares transferred to a revocable trust she controls, classified as exempt under Rule 16a-13, with no sale proceeds involved.

How many CRL shares does CEO Birgit Girshick hold after the reported gifts?

After the gifts, Birgit Girshick holds 36,013 CRL common shares directly and 43,803 shares indirectly through a revocable trust. These figures show her continuing substantial equity exposure despite the transfers being structured as bona fide gifts rather than open-market sales.

Were the CRL Form 4 transactions by the CEO open-market sales?

No, the Form 4 shows bona fide gifts, not open-market sales. The 6,772 shares were transferred without consideration, including an exempt transfer of 3,386 shares to a revocable trust controlled by the CEO under Rule 16a-13, so no trading proceeds were reported.

What is the role of the revocable trust in the CRL CEO’s holdings?

The revocable trust holds 43,803 CRL common shares indirectly for the CEO after the transactions. A 3,386-share transfer to this trust was labeled an exempt Rule 16a-13 transaction, indicating the CEO continues to control the trust while changing the ownership structure.

What stock options does CRL CEO Birgit Girshick report holding?

She reports stock options over 8,722 CRL common shares with an exercise price of $208.44 per share. These options, held directly, are scheduled to expire on May 31, 2034, providing long-term equity-linked exposure in addition to her share holdings.

How significant are the CRL CEO’s gift transfers compared with her remaining position?

The CEO gifted 6,772 CRL shares while retaining 36,013 shares directly and 43,803 indirectly through a trust. This indicates the transfers represent only a portion of her overall reported holdings, which remain sizable after the exempt, non-sale transactions.